文献速递腹部US

混合型肝细胞-胆管细胞癌:能否用超声造影肝脏影像报告与数据系统(LI-RADS)预测患者生存?

Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
PubMed 文献 · Eur Radiol · 2021-01-25

本研究纳入37例经病理证实的混合型肝细胞-胆管细胞癌患者,评估超声造影LI-RADS分类与组织病理成分优势及术后生存的关系。结果显示81.1%肿瘤归为LR-M或LR-TIV,仅18.9%为LR-5;LR-5患者无病生存期显著长于LR-M与LR-TIV合并组(中位18.0 vs 6.4个月,p=0.016)。

要点

  • 超声造影LI-RADS分类中,多数混合型肝细胞-胆管细胞癌表现为LR-M或LR-TIV(81.1%),仅18.9%为LR-5。
  • LR-5组无病生存期显著长于LR-M与LR-TIV合并组(中位18.0 vs 6.4个月,p=0.016)。
  • 多发病灶、肿瘤≥5 cm及LR-M/LR-TIV分类与更短无病生存期独立相关(HR分别为3.1、4.1、4.7)。

核心结论

  • 超声造影表现为LR-5的混合型肝细胞-胆管细胞癌倾向于以肝细胞癌成分为主,且其无病生存期显著长于LR-M和LR-TIV分类者。

研究设计与样本

  • 回顾性分析2011年1月至2018年12月经病理证实的37例混合型肝细胞-胆管细胞癌患者(33男4女,平均年龄50.4±11.0岁)的医学记录和超声造影图像,共37个结节(平均直径6.1±3.9 cm),以组织病理学肿瘤成分优势为参考。

关键影像表现/征象

  • 超声造影LI-RADS分类:62.2%(23/37)为LR-M,18.9%(7/37)为LR-5,18.9%(7/37)为LR-TIV。
  • LR-5组肝细胞癌成分优势比例为100%(10/10),LR-M组为81.5%(22/27),两组差异无统计学意义(p=0.591)。

诊断标准与关键数值

  • 采用美国放射学会超声造影肝脏影像报告与数据系统(CEUS LI-RADS)分类。
  • LR-5组患者中位无病生存期18.0个月,LR-M与LR-TIV合并组中位无病生存期6.4个月,LR-5组显著更长(p=0.016)。
  • 多发病灶与更短无病生存期独立相关(风险比3.1,p=0.007)。
  • 肿瘤大小≥5 cm与更短无病生存期独立相关(风险比4.1,p=0.003)。
  • CEUS LI-RADS分类为LR-M和LR-TIV与更短无病生存期独立相关(风险比4.7,p=0.011)。

临床应用与阅片要点

  • 在超声造影阅片报告中,对混合型肝细胞-胆管细胞癌按CEUS LI-RADS分类,有助于提示术后无病生存期差异。
  • LR-5分类的混合型肝细胞-胆管细胞癌患者无病生存期较长,而LR-M或LR-TIV分类者无病生存期较短。
  • 多发病灶和肿瘤≥5 cm是术后无病生存期较短的独立相关因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the relationship between contrast-enhanced (CE) ultrasound Liver Reporting and Data System (LI-RADS) classification of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and their histopathological component predominance, and to determine if the CEUS LI-RADS category can be used to predict the patient's survival after surgical resection.

METHODS: Between January 2011 and December 2018, medical records and CEUS of patients with pathologically proven cHCC-CCA were studied. The predominance of hepatocellular carcinoma (HCC)/intrahepatic cholangiocarcinoma (ICC) component of cHCC-CCA was analyzed by histopathology. The proportion of HCC-predominant cHCC-CCA in different LI-RADS category was compared by using Fisher's exact test. Factors affecting tumor recurrence were analyzed by Cox proportional hazard model. Disease-free survival (DFS) was estimated by using Kaplan-Meier survival curve and compared by log-rank test.

RESULTS: The study included 37 cHCC-CCA patients (33 men, 4 women; average age, 50.4 ± 11.0 years) and 37 nodules (mean diameter, 6.1 ± 3.9 cm). According to CEUS LI-RADS, 62.2% (23/37), 18.9% (7/37), and 18.9% (7/37) of cHCC-CCA were classified as LR-M, LR-5, and LR-TIV, respectively. The ratio of HCC predominance in LR-5 was 100% (10/10) vs 81.5% (22/27) in the LR-M group (p = 0.591). In our population, LR-5 patients had longer DFS than LR-M and LR-TIV patients combined (median DFS: 18.0 vs 6.4 months, p = 0.016). Multiple lesions (hazard ratio, 3.1; p = 0.007), tumor size (≥ 5 cm, hazard ratio, 4.1; p = 0.003), and CEUS LI-RADS category (LR-M and LR-TIV, hazard ratio, 4.7; p = 0.011) showed independent association with shorter DFS.

CONCLUSION: cHCC-CCA characterized as LR-5 on CEUS tend to represent HCC-predominant tumors with significantly longer disease-free survival compared to cHCC-CCA categorized as LR-M and LR-TIV.

KEY POINTS: • By using the American College of Radiology contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS), majority (30/37, 81.1%) of cHCC-CCA tumors were classified as LR-M or LR-TIV and only 18.9% (7/30) of cHCC-CCA were categorized as LR-5. • Patients with CEUS LR-5 cHCC-CCA had statistically significant longer disease-free time than those with LR-M and TIV cHCC-CCA (median DFS: 18.0 vs 6.4 months, p = 0.016). • Multiple lesions (hazard ratio, 3.1; p = 0.007), tumor size (≥ 5 cm, hazard ratio, 4.1; p = 0.003), and CEUS LI-RADS category (LR-M and LR-TIV, hazard ratio, 4.7; p = 0.011) showed independent association with shorter DFS.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang J, Huang JY, Chen X, et al. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival? Eur Radiol. 2021. PMID: 33492470. doi:10.1007/s00330-020-07656-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。